Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
21:58:59 EDT Mon 06 May 2024
Enter Symbol
or Name
USA
CA



News for U:ONCY from 2023-05-07 to 2024-05-06 - 69 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2024-04-30 07:00U:ONCYNews ReleaseOncolytics Biotech(TM) to Host Conference Call to Discuss First Quarter Financial Results and Recent Operational Highlights
2024-04-30 07:00U:ONCYNews ReleaseOncolytics Biotech(TM) to Host Conference Call to Discuss First Quarter Financial Results and Recent Operational Highlights
2024-04-25 07:00U:ONCYNews ReleaseOncolytics Biotech(TM) Announces Upcoming Presentations at the American Society of Clinical Oncology Annual Meeting
2024-04-25 07:00U:ONCYNews ReleaseOncolytics Biotech(TM) Announces Upcoming Presentations at the American Society of Clinical Oncology Annual Meeting
2024-04-11 07:00U:ONCYNews ReleaseOncolytics Biotech(TM) Advances Toward Registration-Enabling Trial for Pelareorep in Breast Cancer with Submission of Type C Meeting Request to FDA
2024-04-11 07:00U:ONCYNews ReleaseOncolytics Biotech(TM) Advances Toward Registration-Enabling Trial for Pelareorep in Breast Cancer with Submission of Type C Meeting Request to FDA
2024-04-02 07:00U:ONCYNews ReleaseOncolytics Biotech(TM) to Participate in a Panel Presentation at Canaccord Genuity's Horizons in Oncology Virtual Conference
2024-04-02 07:00U:ONCYNews ReleaseOncolytics Biotech(TM) to Participate in a Panel Presentation at Canaccord Genuity's Horizons in Oncology Virtual Conference
2024-03-07 16:01U:ONCYNews ReleaseOncolytics Biotech(TM) Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights
2024-03-07 16:01U:ONCYNews ReleaseOncolytics Biotech(TM) Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights
2024-03-05 08:30U:ONCYNews ReleaseIncreasing Incidence of Pancreatic Cancer Leading to a $6.85 Billion Dollar Market Size for New Treatments
2024-03-05 07:00U:ONCYNews ReleaseOncolytics Biotech(TM) Files Amendment to Initiate New Pancreatic Cancer GOBLET Cohort Supported by PanCAN
2024-03-05 07:00U:ONCYNews ReleaseOncolytics Biotech(TM) Files Amendment to Initiate New Pancreatic Cancer GOBLET Cohort Supported by PanCAN
2024-03-04 07:00U:ONCYNews ReleaseOncolytics Biotech(TM) to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results and Recent Operational Highlights
2024-03-04 07:00U:ONCYNews ReleaseOncolytics Biotech(TM) to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results and Recent Operational Highlights
2024-02-28 07:00U:ONCYNews ReleaseOncolytics Biotech(TM) Announces Presentation at the Cancer Advocacy Group of Louisiana's 3rd Annual NeauxCancer Conference
2024-02-28 07:00U:ONCYNews ReleaseOncolytics Biotech(TM) Announces Presentation at the Cancer Advocacy Group of Louisiana's 3rd Annual NeauxCancer Conference
2024-02-14 08:30U:ONCYNews ReleaseAnal Cancer Treatment Market Expected to Reach $1.63 Billion by 2030 as Latest Clinical Studies Focus on New Therapies
2024-02-14 07:00U:ONCYNews ReleaseOncolytics Biotech ® Initiates Enrollment Expansion of GOBLET Anal Cancer Cohort
2024-02-14 07:00U:ONCYNews ReleaseOncolytics Biotech ‚ ® Initiates Enrollment Expansion of GOBLET Anal Cancer Cohort
2024-01-09 10:25U:ONCYNews ReleaseGlobal Oncology Cancer Drugs Market Revenue Projected To Surpass $289 Billion By 2030
2024-01-09 07:00U:ONCYNews ReleaseOncolytics Biotech ® Appoints Patricia S. Andrews to its Board of Directors
2024-01-09 07:00U:ONCYNews ReleaseOncolytics Biotech ‚ ® Appoints Patricia S. Andrews to its Board of Directors
2024-01-04 07:00U:ONCYNews ReleaseOncolytics Biotech ® Recaps 2023 Accomplishments, Provides Outlook for 2024
2024-01-04 07:00U:ONCYNews ReleaseOncolytics Biotech ‚ ® Recaps 2023 Accomplishments, Provides Outlook for 2024
2023-12-07 07:00U:ONCYNews ReleaseOncolytics Biotech ® and SOLTI Present Positive Translational Data at SABCS
2023-12-07 07:00U:ONCYNews ReleaseOncolytics Biotech ‚ ® and SOLTI Present Positive Translational Data at SABCS
2023-11-09 07:00U:ONCYNews ReleaseOncolytics Announces the Anal Cancer Cohort of the GOBLET Phase 1/2 Study of Pelareorep and Atezolizumab Has Met the Success Criteria for Efficacy
2023-11-09 07:00U:ONCYNews ReleaseOncolytics Announces the Anal Cancer Cohort of the GOBLET Phase 1/2 Study of Pelareorep and Atezolizumab Has Met the Success Criteria for Efficacy
2023-11-09 06:30U:ONCYNews ReleaseOncolytics Provides Update on Pancreatic Cancer Program for Pelareorep
2023-11-09 06:30U:ONCYNews ReleaseOncolytics Provides Update on Pancreatic Cancer Program for Pelareorep
2023-11-03 12:03U:ONCYNews ReleaseOncolytics Biotech ® and SOLTI Present Further Positive Pelareorep Translational Data at SITC
2023-11-03 12:03U:ONCYNews ReleaseOncolytics Biotech ‚ ® and SOLTI Present Further Positive Pelareorep Translational Data at SITC
2023-11-03 07:00U:ONCYNews ReleaseOncolytics Biotech ® Reports Third Quarter 2023 Financial Results and Operational Highlights
2023-11-03 07:00U:ONCYNews ReleaseOncolytics Biotech ‚ ® Reports Third Quarter 2023 Financial Results and Operational Highlights
2023-10-23 07:05U:ONCYNews ReleaseOncolytics Presents Positive Updated Pancreatic Cancer Data from GOBLET Phase 1/2 Study at ESMO
2023-10-23 07:05U:ONCYNews ReleaseOncolytics Presents Positive Updated Pancreatic Cancer Data from GOBLET Phase 1/2 Study at ESMO
2023-10-23 07:00U:ONCYNews ReleaseOncolytics Achieves Success Criteria for Efficacy in the Third-Line Colorectal Cancer Cohort of the GOBLET Study
2023-10-23 07:00U:ONCYNews ReleaseOncolytics Achieves Success Criteria for Efficacy in the Third-Line Colorectal Cancer Cohort of the GOBLET Study
2023-10-20 07:00U:ONCYNews ReleaseOncolytics Biotech ® to Host Conference Call to Discuss Third Quarter Financial Results and Recent Operational Highlights
2023-10-20 07:00U:ONCYNews ReleaseOncolytics Biotech ‚ ® to Host Conference Call to Discuss Third Quarter Financial Results and Recent Operational Highlights
2023-10-16 07:00U:ONCYNews ReleaseOncolytics Biotech ® To Present Two Posters on the Pelareorep-Based GOBLET Study at ESMO 2023
2023-10-16 07:00U:ONCYNews ReleaseOncolytics Biotech ‚ ® To Present Two Posters on the Pelareorep-Based GOBLET Study at ESMO 2023
2023-09-26 08:00U:ONCYNews ReleaseTHE PANCREATIC CANCER ACTION NETWORK SELECTS ONCOLYTICS BIOTECH ‚ ® INC. TO RECEIVE $5 MILLION THERAPEUTIC ACCELERATOR AWARD TO DEVELOP LEADING-EDGE TREATMENTS
2023-09-26 07:00U:ONCYNews ReleaseTHE PANCREATIC CANCER ACTION NETWORK SELECTS ONCOLYTICS BIOTECH ® INC. TO RECEIVE $5 MILLION THERAPEUTIC ACCELERATOR AWARD TO DEVELOP LEADING-EDGE TREATMENTS
2023-09-26 07:00U:ONCYNews ReleaseTHE PANCREATIC CANCER ACTION NETWORK SELECTS ONCOLYTICS BIOTECH ‚ ® INC. TO RECEIVE $5 MILLION THERAPEUTIC ACCELERATOR AWARD TO DEVELOP LEADING-EDGE TREATMENTS
2023-09-19 07:00U:ONCYNews ReleaseOncolytics Biotech ® Announces Fireside Chat at the Cantor Global Healthcare Conference
2023-09-19 07:00U:ONCYNews ReleaseOncolytics Biotech ‚ ® Announces Fireside Chat at the Cantor Global Healthcare Conference
2023-09-07 09:22U:ONCYNews ReleaseOncolytics Biotech ® Announces Full Exercise of Over-Allotment Option from Public Offering
2023-09-06 07:00U:ONCYNews ReleaseOncolytics Biotech ® to Participate in a Fireside Chat at the H.C. Wainwright 25th Annual Global Investment Conference
2023-09-06 07:00U:ONCYNews ReleaseOncolytics Biotech ‚ ® to Participate in a Fireside Chat at the H.C. Wainwright 25th Annual Global Investment Conference
2023-08-14 07:00U:ONCYNews ReleaseOncolytics Biotech ® Reports Second Quarter 2023 Financial Results and Operational Highlights
2023-08-14 07:00U:ONCYNews ReleaseOncolytics Biotech ‚ ® Reports Second Quarter 2023 Financial Results and Operational Highlights
2023-08-08 08:50U:ONCYNews ReleaseOncolytics Biotech ® Successfully Raises US$15 Million to Advance Breast and Pancreatic Cancer Clinical Programs
2023-08-04 07:05U:ONCYNews ReleaseOncolytics Biotech ® to Participate in a Fireside Chat at Canaccord Genuity's 43rd Annual Growth Conference
2023-08-04 07:05U:ONCYNews ReleaseOncolytics Biotech ‚ ® to Participate in a Fireside Chat at Canaccord Genuity's 43rd Annual Growth Conference
2023-08-04 07:00U:ONCYNews ReleaseOncolytics Biotech ® to Host Conference Call to Discuss Second Quarter Financial Results and Recent Operational Highlights
2023-08-04 07:00U:ONCYNews ReleaseOncolytics Biotech ‚ ® to Host Conference Call to Discuss Second Quarter Financial Results and Recent Operational Highlights
2023-07-31 06:55U:ONCYNews ReleaseOncolytics Biotech ® Announces US$15 Million Bought Deal Offering of Units
2023-06-22 07:00U:ONCYNews ReleaseOncolytics Biotech's ® Pelareorep Selected for Inclusion in Precision PromiseSM Pivotal Phase 3 Platform Trial
2023-06-22 07:00U:ONCYNews ReleaseOncolytics Biotech's ‚ ® Pelareorep Selected for Inclusion in Precision PromiseSM Pivotal Phase 3 Platform Trial
2023-06-05 07:00U:ONCYNews ReleaseOncolytics Biotech ® Announces Updated Randomized Phase 2 Data from BRACELET-1 Metastatic Breast Cancer Trial that Show Pelareorep Driving Robust Increases in Progression-Free Survival and Confirmed Overall Response Rate
2023-06-05 07:00U:ONCYNews ReleaseOncolytics Biotech ‚ ® Announces Updated Randomized Phase 2 Data from BRACELET-1 Metastatic Breast Cancer Trial that Show Pelareorep Driving Robust Increases in Progression-Free Survival and Confirmed Overall Response Rate
2023-05-26 11:30U:ONCYNews ReleaseOncolytics Biotech ® to Host Key Opinion Leader Webinar on Data from the Randomized BRACELET-1 Trial in HR+/HER2- Metastatic Breast Cancer Being Presented at the Upcoming ASCO Annual Meeting
2023-05-26 11:30U:ONCYNews ReleaseOncolytics Biotech ‚ ® to Host Key Opinion Leader Webinar on Data from the Randomized BRACELET-1 Trial in HR+/HER2- Metastatic Breast Cancer Being Presented at the Upcoming ASCO Annual Meeting
2023-05-25 17:41U:ONCYNews ReleaseOncolytics Biotech ® Announces Positive Randomized Phase 2 Data from BRACELET-1 Metastatic Breast Cancer Trial Demonstrating Pelareorep Drives =50% Improvements in ORR and mPFS in an ASCO Annual Meeting Abstract
2023-05-25 17:41U:ONCYNews ReleaseOncolytics Biotech ‚ ® Announces Positive Randomized Phase 2 Data from BRACELET-1 Metastatic Breast Cancer Trial Demonstrating Pelareorep Drives ¢ ‰ ¥50% Improvements in ORR and mPFS in an ASCO Annual Meeting Abstract
2023-05-10 07:00U:ONCYNews ReleaseOncolytics Biotech ® Announces Voting Results from the Annual General Meeting of Shareholders
2023-05-10 07:00U:ONCYNews ReleaseOncolytics Biotech ‚ ® Announces Voting Results from the Annual General Meeting of Shareholders